standard or the IRP for calibration. Consequently, the present study shows once again that standardization and/or recalibration of immunoassays in general is difficult to achieve with a common calibrator alone but needs split-sample measurements with a reference measurement procedure. This stems from the well-known fact that immunoassays may suffer from differences in behavior related to differences between the matrices of calibrators and those of real samples (1 ) .
Standardization/recalibration makes sense only when sufficient correlation of the investigated immunoassay is achieved with the comparison measurement procedure (or sufficient specificity). As shown in Table 1 , this prerequisite was fulfilled in the present study because all assays had an excellent second-order correlation with the ID-LC-MS/MS measurement procedure (0.980 Ͻ r Ͻ 0.992). The outcome of the recalibration of the test systems, which was done by use of the respective secondorder regression equations (Table 1) , is shown in Fig. 1B . As can be seen from Fig. 1B , all test systems were successfully recalibrated by this approach.
Standardization cannot solve specificity/interference problems in immunoassays. Indeed, in this study, three samples showed considerable sample-related effects in the immunoassays because of properties of the matrix. Investigation of the reasons to which the phenomenon can be attributed was beyond the scope of this study.
The present ID-LC-MS/MS measurement procedure does not yet have the status of a reference measurement procedure. It is not part of a complete reference system comprising an international primary calibrator such as the IRP 84/510. As described, the ID-LC-MS/MS measurement procedure used here was calibrated with a commercial C-peptide preparation. This was done, on the one hand, for economic reasons; on the other hand, it was also done because we did not consider the current C-peptide IRP superior to the commercial calibrator. The IRP, being a recombinant product, contains an impurity of 10%, and the ampoule content was only nominally assigned the value of 10 g by comparison with several commercial C-peptide preparations. Ideally, a primary calibrator should be certified in terms of mass units by techniques such as amino acid analysis and MS.
Another reason that the ID-LC-MS/MS measurement procedure used here cannot be claimed as a reference measurement procedure is that, as part of the validation process, it should be assessed in a round-robin trial for its ability to satisfy predefined performance specifications in terms of trueness/accuracy and precision. Such an assessment should preferably be endorsed by an authoritative organization (8, 9 ) .
In conclusion, the present study demonstrates that a method comparison with a real reference measurement procedure would be the ideal basis for standardization/ recalibration of test systems. Alternatively, it can guide manufacturers in judging whether their assays are sufficiently specific and need recalibration. If this is done, one would also naturally measure the calibrators to support the industry in their standardization process and to get information about assay commutability. For the latter, a deviation from the reference measurement procedure values in a defined mathematical way is required. The ID-LC-MS/MS for quantification of urinary C-peptide appears useful for recalibration of immunoassay test systems. It could thus provide an excellent basis for a reference measurement procedure. The accurate antenatal prediction of fetal lung maturity (FLM) based on results from amniotic fluid samples is of utmost importance in the prevention of neonatal respiratory distress syndrome and its complications. The current "gold standard" for the determination of FLM is the evaluation of phospholipids (i.e., measurement of lecithin/sphingomyelin ratio and quantification of phosphatidylglycerol) in amniotic fluid samples by thin-layer chromatography. These tests are, however, time-consuming and not continuously available at most institutions. Lamellar bodies are lamellated phospholipids that represent a storage form of surfactant (1 ) . Because lamellar body diameter (range, 1-5 m) is similar to that of small platelets, lamellar body counts (LBCs) can be obtained rapidly with use of the platelet channel of a hematology analyzer (2 ) .
Lamellar Body Count in
Recently, a consensus LBC protocol was published, and a FLM cutoff of 50 000/L was suggested without discussion regarding the hematology analyzer used (3 ). The majority of published reports to date have used a Coulter brand of hematology analyzer to establish clinical decision limits (2, 4 -13 ) . The published experience with other hematology analyzers, such as the Sysmex NE-1500 (14 ) , for obtaining LBCs is limited. One study used LBCs from three different analyzers (two from Coulter, one from Sysmex) to assess FLM without providing any evidence that the instrumentation was not a source of imprecision (9 ) . Our objective was therefore to compare LBC concordance from the following four hematology analyzers: Coulter Gen-S (Beckman Coulter), Sysmex XE-2100 (Sysmex), Cell-dyn 3500 (Abbott Laboratories), and ADVIA 120 (Bayer Corporation).
Leftover amniotic fluid samples sent to the BarnesJewish Hospital Laboratory for physician-ordered FLM analysis during a 4-month period were analyzed. Amniotic fluid samples with visible blood and/or meconium contamination, measurable hemoglobin (Ͼ0.01 g/L; Coulter Gen-S), or insufficient volume (Ͻ500 L) were excluded. Samples were stored at 4°C. Forty-four amniotic fluid samples were evaluated. Uncentrifuged samples were assayed on the four hematology analyzers within 10 days of receipt (median, 4 days; range, 1-10 days). A previous study confirmed that results of lamellar body counts performed on amniotic fluid stored at 4°C were stable up to 10 days (15 ) . Human studies committee approval was obtained for this study.
Intra-and interassay imprecision (as CVs) was evaluated by two approaches. The intraassay imprecision for platelet counts was first determined with an EDTA-whole blood sample manipulated to obtain a platelet count of ϳ40 000/L. Measured platelet counts were as follows: Coulter Gen-S, mean (SD), 39 000 (2400)/L (n ϭ 6; CV ϭ 6.1%); Sysmex XE-2100, 43 200 (1300)/L (n ϭ 5; CV ϭ 3.0%); ADVIA 120, 48 500 (1900)/L (n ϭ 6; CV ϭ 3.9%); and Cell-dyn 3500, 36 500 (1600)/L (n ϭ 5; CV ϭ 4.3%). Intraassay imprecision for LBCs was determined using a pooled amniotic fluid sample. Results were as follows: Coulter Gen-S, mean (SD), 18 400 (500)/L (n ϭ 7; CV ϭ 2.9%); Sysmex XE-2100, 13 900 (600)/L (n ϭ 7; CV ϭ 4.6%); ADVIA 120, 12 965 (855)/L (n ϭ 6; CV ϭ 6.6%); and Cell-dyn 3500, 31 300 (2100)/L (n ϭ 7; CV ϭ 6.7%).
Interassay imprecision for the Coulter Gen-S was also determined with the manufacturer-supplied abnormal CBC control, diluted 1:1 with Isoton buffer (performed in duplicate on 10 separate days): mean (SD), 35 000 (1330)/L (CV ϭ 3.8%).
LBC results for the 44 different amniotic fluid samples are shown in Table 1 . Using published guidelines for FLM based on LBCs performed on Coulter hematology analyzers (3 ), we determined the concordance of LBCs between the three other hematology analyzers and the Coulter Gen-S (Table 1 and Fig. 1, A-C) . Fourteen were considered mature (Coulter GEN-S LBC Ն50 000/L), 21 intermediate (Coulter GEN-S LBC 15 000 -50 000/L), and 9 immature (Coulter GEN-S LBC Յ15 000/L). For the ADVIA 120, the LBC was expressed as platelet count plus red blood cell ghosts and fragments (calculated LBC), as recommended by the manufacturer. Of the three analyzers, the Sysmex XE-2100 showed the best concordance (86%) with the Coulter Gen-S (Fig. 1A) . The concordance of the ADVIA 120 (calculated LBC) was 78% (Fig. 1B) . When uncorrected ADVIA platelet counts were analyzed, the concordance with Coulter Gen-S was only 63% (data not shown). Finally, the concordance of the Cell-dyn 3500 with the Coulter Gen-S was 66% (Fig. 1C) .
To assess the difference between the Coulter Gen-S and the other three instruments, we derived Bland-Altmanlike plots (Fig. 1, D-F) . The statistical difference was assessed using the least-squares regression method. With a slope of Ϫ0.32 (95% confidence interval, Ϫ0.39 to Ϫ0.26; P Ͻ0.001), the difference between the Sysmex XE-2100 and the Coulter Gen-S LBC values was negative (Fig. 1D) . For the ADVIA 120 (calculated LBC) values, the slope was Ϫ0.46 (95% confidence intervals, Ϫ0.60 to Ϫ0.32; P Ͻ0.001) compared with the Coulter Gen-S (Fig. 1E) . By contrast, the difference between the Cell-dyn 3500 and Coulter Gen-S LBC values was positive (slope, 0.76; 95% confidence interval, 0.66 -0.87; P Ͻ0.001; Fig. 1F ).
The mechanisms underlying these differences are unknown but are likely related to the way lamellar bodies are counted on each instrument. The four hematology analyzers use different principles to identify platelets. The ADVIA 120 measures two light-scatter angles of particles as they pass through a laser beam (optical analysis). Platelets are identified based on their volume and refractive index (16 ) . Platelet counts include platelets with volumes up to 60 fL and exclude other similarly sized particles, such as red blood cell fragments. Thus, the LBC count on the ADVIA 120 was derived as the sum of all platelet-sized particles measured in the PLT channel (calculated LBC). In contrast, the CBC channels on the Sysmex XE-2100 and the Coulter Gen-S use impedance technology. The Coulter method (conventional impedance) counts particles by detecting changes in electrical resistance when a particle in a conductive liquid goes through a small aperture (17 ) . The size of the electrical pulse generated is proportional to the particle volume. Platelets are identified based on their volume (2-20 fL). The Sysmex technology is different from the Coulter method in that it simultaneously detects conventional (direct current) and radiofrequency impedance (18 ) . The latter is thought to reflect intracellular changes. The Cell-dyn 3500 combines optical scatter and impedance to increase the accuracy of particle counting (19 ) . The hematology analyzers evaluated in this study produced accurate and precise platelet counts in reference populations (20 ) and thrombocytopenic patients (21 ) despite measuring different physical properties. However, our data indicate that the concordance among instruments for enumerating lamellar bodies is poor. In summary, it is clear that different hematology analyzers count lamellar bodies differently. It will be necessary to establish analyzer-specific LBC clinical decision limits that are confirmed by outcome-based studies. S100B is an acidic calcium-binding protein of the EF-hand family present in the central nervous system, where it is located mainly in glial cells (1 ) . It has been suggested that the protein is involved in various cellular functions, but precisely which is still a matter of debate. The protein has been found to act at physiologic concentrations as a cytokine with a neurotrophic role in experimental models, in cell cultures, and in biological fluids such as cord blood, peripheral blood, and urine (1) (2) (3) (4) . This hypothesis has been corroborated by measurements of S100B protein Clinical Chemistry 49, No. 6, 2003 
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